ImmunityBio (IBRX) presents at ASCO Annual Meeting
New narrative with limited coverage — still forming.
Sentiment Timeline
Event Timeline
Hypotheses
IBRX analyst coverage will expand with at least 2 new 'Buy' or 'Outperform' ratings issued within 90 days following ASCO presentation, reflecting confidence in pipeline progress communicated at the meeting
IBRX will receive increased institutional investor interest measured by options implied volatility (IV) expansion to 55+ range within 60 days post-ASCO presentation, indicating market expectations for significant near-term catalyst
IBRX stock price will experience a positive momentum of at least 8% within 30 days following the ASCO Annual Meeting presentation due to positive clinical trial data disclosure or favorable analyst sentiment